Marta Weinstock-Rosin
Direttore/Membro del Consiglio presso Avraham Pharmaceuticals Ltd.
Profilo
Marta Weinstock-Rosin is the founder of Spero Biopharma Ltd.
She is currently a Director at Avraham Pharmaceuticals Ltd.
and a Professor-Emeritus at The Hebrew University of Jerusalem.
Previously, she served as the President of The Israel Society for Neuroscience from 2005 to 2005.
Posizioni attive di Marta Weinstock-Rosin
| Società | Posizione | Inizio |
|---|---|---|
Avraham Pharmaceuticals Ltd.
 Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Direttore/Membro del Consiglio | - |
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - |
Precedenti posizioni note di Marta Weinstock-Rosin
| Società | Posizione | Fine |
|---|---|---|
| The Israel Society for Neuroscience | Presidente | 01/01/2005 |
Spero Biopharma Ltd.
 Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Fondatore | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
| The Israel Society for Neuroscience | |
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |
Spero Biopharma Ltd.
Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Health Technology |
- Borsa valori
- Insiders
- Marta Weinstock-Rosin
